Identification and characterization of five-transmembrane isoforms of human vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors

被引:29
|
作者
Bokaei, Payman Baradar
Ma, Xue-Zhong
Byczynski, Bartosz
Keller, Jeremy
Sakac, Darinka
Fahim, Soad
Branch, Donald R.
机构
[1] Toronto Gen Res Inst, Div Cell & Mol Biol, Toronto, ON M5G 2M1, Canada
[2] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada
[3] Canadian Red Cross Blood Transfus Serv, Toronto, ON M5G 2M1, Canada
[4] Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada
[5] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada
关键词
vasoactive intestinal peptide receptors; splice variants; five-transmembrane; VIPR1; VPAC1; VIPR2; VPAC2; GPCR;
D O I
10.1016/j.ygeno.2006.07.008
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The seven- transmembrane (7TM) G-protein-coupled neuroendocrine receptors VPAC1 (HGNC approved gene symbol VIPR1) and VPAC2 (HGNC approved gene symbol VIPR2) are expressed in different tissues and involved in the regulation of important biological functions. We now report the identification and characterization of novel five-transmembrane(5TM) forms of both human VPAC1 and human VPAC2. These alternatively spliced variant mRNAs result from the skipping of exons 10/11, spanning the third intracellular loop, the fourth extracellular loop, and the transmembrane regions 6 and 7, producing in-frarne 5TM receptors predicted to lack a G-protein-binding motif. RT-PCR showed that these 5TM receptors are differentially expressed in transformed and normal cells. Translation of the 5TM protein was demonstrated by transfection and expression in CHO cells. Following agonist stimulation, differential signaling of the 7TM versus 5TM forms was shown both for the activation of adenylate cyclase and for tyrosine phosphorylation. The identification of these splice variants in various cells and their expression and differential signal transduction compared to the 7TM form suggest that these novel receptors have biological relevance. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:791 / 800
页数:10
相关论文
共 50 条
  • [41] Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide attenuate glutamate-induced nNOS activation and cytotoxicity
    Onoue, S
    Endo, K
    Yajima, T
    Kashimoto, K
    REGULATORY PEPTIDES, 2002, 107 (1-3) : 43 - 47
  • [42] Central administration of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide differentially regulates energy metabolism in chicks
    Tachibana, Tetsuya
    Oikawa, Daichi
    Adachi, Nami
    Boswell, Tim
    Furuse, Mitsuhiro
    COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY A-MOLECULAR & INTEGRATIVE PHYSIOLOGY, 2007, 147 (01): : 156 - 164
  • [43] Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide and Vasoactive Intestinal Peptide Against Cognitive Decline in Neurodegenerative Diseases
    Soles-Tarres, Irene
    Cabezas-Llobet, Nuria
    Vaudry, David
    Xifro, Xavier
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2020, 14
  • [44] Central pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) decrease the baroreflex sensitivity in trout
    Lancien, Frederic
    Mimassi, Nagi
    Conlon, J. Michael
    Le Mevel, Jean-Claude
    GENERAL AND COMPARATIVE ENDOCRINOLOGY, 2011, 171 (02) : 245 - 251
  • [45] Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity
    Ganea, D
    Delgado, M
    CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE, 2002, 13 (03) : 229 - 237
  • [46] Estrogens impair hypophagia and hypothalamic cell activation induced by vasoactive intestinal peptide, but not by pituitary adenylate cyclase-activating polypeptide
    Garnica-Siqueira, Marcela Cristina
    Martins, Andressa Busetti
    Monteiro, Erica Cristina Alves Munhoz
    de Oliveira, Maria Heloisa Bernardes
    Baratto, Carolina dos Reis
    Tsutsui, Fabiano Takeo Komay
    de Oliveira, Lucas Leonardo Franca
    Stopa, Larissa Rugila dos Santos
    de Souza, Camila Franciele
    Wunderlich, Ana Luiza Machado
    Zaia, Dimas Augusto Morozin
    Leite, Cristiane Mota
    Zaia, Cassia Thais Bussamra Vieira
    Uchoa, Ernane Torres
    PEPTIDES, 2025, 183
  • [47] Involvement of pituitary adenylate cyclase-activating polypeptide II vasoactive intestinal peptide 2 receptor in mouse neocortical astrocytogenesis
    Zupan, V
    Hill, JM
    Brenneman, DE
    Gozes, I
    Fridkin, M
    Robberecht, P
    Evrard, P
    Gressens, P
    JOURNAL OF NEUROCHEMISTRY, 1998, 70 (05) : 2165 - 2173
  • [48] Multiple human receptors for pituitary adenylyl cyclase-activating polypeptide and vasoactive intestinal peptide are expressed in a tissue-specific manner
    Wei, Y
    Mojsov, S
    VIP, PACAP, AND RELATED PEPTIDES, 2ND INTERNATIONAL SYMPOSIUM, 1996, 805 : 624 - 627
  • [49] Effect of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide on mouse preantral follicle development in vitro
    Cecconi, S
    Rossi, G
    Barberi, M
    Scaldaferri, L
    Canipari, R
    ENDOCRINOLOGY, 2004, 145 (04) : 2071 - 2079
  • [50] REGIONAL HEMODYNAMIC-RESPONSES TO PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE AND VASOACTIVE INTESTINAL POLYPEPTIDE IN CONSCIOUS RATS
    GARDINER, SM
    RAKHIT, T
    KEMP, PA
    MARCH, JE
    BENNETT, T
    BRITISH JOURNAL OF PHARMACOLOGY, 1994, 111 (02) : 589 - 597